Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Creative Commons License

Teerlink J. R., Diaz R., Felker G. M., McMurray J. J. V., Metra M., Solomon S. D., ...Daha Fazla

EUROPEAN JOURNAL OF HEART FAILURE, cilt.22, sa.11, ss.2160-2171, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 11
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1002/ejhf.2015
  • Dergi Adı: EUROPEAN JOURNAL OF HEART FAILURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2160-2171
  • Anahtar Kelimeler: Heart failure, Omecamtiv mecarbil, Cardiac myosin activator, Inotrope, Myotrope, Cardiovascular outcomes trial, CARDIAC MYOSIN ACTIVATOR, INCREASE CONTRACTILITY, TOLVAPTAN, MORTALITY, OUTCOMES, PHASE-2, WOMEN
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.